Autoinflammatory Skin Disorders in Inflammatory Bowel Diseases, Pyoderma Gangrenosum and Sweet’s Syndrome: a Comprehensive Review and Disease Classification Criteria

2013 ◽  
Vol 45 (2) ◽  
pp. 202-210 ◽  
Author(s):  
Angelo V. Marzano ◽  
Rim S. Ishak ◽  
Simone Saibeni ◽  
Carlo Crosti ◽  
Pier Luigi Meroni ◽  
...  
Keyword(s):  
Pyoderma Gangrenosum ◽  
Inflammatory Bowel Diseases ◽  
Classification Criteria ◽  
Disease Classification ◽  
Sweet’S Syndrome ◽  
Skin Disorders ◽  
Comprehensive Review ◽  
Sweet's Syndrome ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Coexistence of Giant Cell Arteritis with Aortitis and Sweet’s Syndrome: Is It a Coincidence?

2021 ◽  
pp. 9-13
Author(s):  
Abir Derbel ◽  
Chifa Damak ◽  
Mouna Snoussi ◽  
Faten Frikha ◽  
Slim Charfi ◽  
...  
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Inflammatory Bowel Diseases ◽  
Unusual Case ◽  
Rare Disorder ◽  
Sweet’S Syndrome ◽  
Sweet's Syndrome ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Rheumatoid Diseases

Sweet’s syndrome (SS) is a rare disorder characterized by dermal infiltration by neutrophils. It has been reported in association with drugs, malignancies, infections, rheumatoid diseases, inflammatory bowel diseases. Its association with giant cell arteritis (GCA) hasn’t been reported to our knowledge. The diagnosis of GCA was based on inflammatory biological syndrome with aortitis with negative infectious investigations. Herein, we present an unusual case of SS associated with GCA treated with steroids with good outcomes.

Significance of Erythema Nodosum and Pyoderma Gangrenosum in Inflammatory Bowel Diseases

Medicine ◽  
2008 ◽  
Vol 87 (5) ◽  
pp. 281-293 ◽  
Author(s):  
David Farhi ◽  
Jacques Cosnes ◽  
Nada Zizi ◽  
Olivier Chosidow ◽  
Philippe Seksik ◽  
...  
Keyword(s):  
Pyoderma Gangrenosum ◽  
Inflammatory Bowel Diseases ◽  
Erythema Nodosum ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Pyoderma gangrenosum ‒ cutaneous and extracutaneous manifestations

2019 ◽  
Vol 1 (1) ◽  
pp. 7-9
Author(s):  
Klaudia Dopytalska ◽  
Piotr Sobolewski ◽  
Marek Roszkiewicz ◽  
Agata Mikucka-Wituszyńska ◽  
Elżbieta Szymańska ◽  
...  
Keyword(s):  
Pain Management ◽  
Pyoderma Gangrenosum ◽  
Inflammatory Bowel Diseases ◽  
Wound Care ◽  
Neutrophilic Dermatosis ◽  
Biological Therapies ◽  
Haematological Malignancies ◽  
Cutaneous Lesions ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Pyoderma gangrenosum (PG) is a rare, neutrophilic dermatosis with extracutaneous manifestations and associated systemic disorders, including inflammatory bowel diseases, arthritis and haematological malignancies. The pathogenesis of PG is still not fully understood. The cutaneous lesions are often polymorphic and include papules, nodules, sterile pustules with erythematous induration, which quickly evolve into necrotic painful ulcerations. PG can also affect lungs, spleen, liver, pancreas, kidneys, bones and eyes. The treatment of PG is long and challenging and involves the use of sytemic corticoteroids, immunosupressive drugs and biological therapies with concomitant pain management and wound care.

scholarly journals Ustekinumab Successfully Treats and Maintains Remission of Pyostomatitis Vegetans Associated with Crohn’s Disease

2020 ◽  
Vol 2 (1) ◽  
Author(s):  
Sarah Abi Doumeth ◽  
Ossama Abbas ◽  
Jana G Hashash
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Pyoderma Gangrenosum ◽  
Inflammatory Bowel Diseases ◽  
Pyostomatitis Vegetans ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Biochemical Remission

Abstract Pyostomatitis vegetans (PV) is a rare inflammatory stomatitis often associated with inflammatory bowel diseases (IBD). Treatment of PV depends on the presence of coexisting IBD. To date, there have been no reports on the use of ustekinumab for PV. There have been recent cases on the use of ustekinumab for treatment of pyoderma gangrenosum and uveitis. We report the case of a 26-year-old female with moderately severe Crohn’s disease (CD) and PV who was successfully treated with ustekinumab monotherapy. Since initiation of ustekinumab, she has been in clinical and biochemical remission from a CD and PV standpoint for the last 12 months.

Sign in / Sign up

Export Citation Format

Share Document